Clinical Trials Management Today's Research... Tomorrow's Cures

Relationships & Accomplishments

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

August 9, 2022 | Posted in: Relationships & Accomplishments
  Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis ... » Read More


CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension

August 9, 2022 | Posted in: Relationships & Accomplishments
  CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension ... » Read More


FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

August 1, 2022 | Posted in: Relationships & Accomplishments
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older PDF Version ... » Read More


Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

June 30, 2022 | Posted in: Relationships & Accomplishments
  Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica  ... » Read More


FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

May 2, 2022 | Posted in: Relationships & Accomplishments
                  FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only... » Read More


SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022

February 14, 2022 | Posted in: Relationships & Accomplishments
Download as PDF Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo fo... » Read More


FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

January 11, 2022 | Posted in: Relationships & Accomplishments
FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis December 22, 2021 at 4:01 PM EST FDA has set a t... » Read More


New Data Confirms Strong and Long-Lasting Protection of Johnson & Johnson COVID-19 Vaccine

September 21, 2021 | Posted in: Relationships & Accomplishments
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. Additional data ... » Read More


Myovant Sciences Announces European Commission Approval for RYEQO®

July 21, 2021 | Posted in: Relationships & Accomplishments
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids July 20, 2021 02:00 ET | Source: Myovant Sciences, Inc. ... » Read More


Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine

July 7, 2021 | Posted in: Relationships & Accomplishments
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response Demonstrated stron... » Read More


« Previous 1 2 3 Next »